ANVISA Orders Seizure of Unregistered Lipoland Medication in Brazil
Summary
ANVISA ordered the seizure of Lipoland (Tizerpartida) medication in all presentations and dosages on April 22, 2026. The product has no registration in Brazil and is produced by an unknown company. The regulatory measure also prohibits the importation, commercialization, distribution, advertising, and use of the medication nationwide. As an unregistered medication, there are no guarantees of safety and efficacy standards.
About this source
GovPing monitors Brazil ANVISA for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 14 changes logged to date.
What changed
ANVISA issued Resolução RE n° 1,616 on April 17, 2026, mandating the seizure of Lipoland (Tizerpartida) in all presentations and dosages. The medication lacks registration in Brazil and is produced by an unidentified company. The resolution further prohibits importation, commercialization, distribution, advertising, and use of the medication throughout the country.\n\nPharmaceutical importers, distributors, and healthcare providers handling Lipoland should immediately cease all activities related to this product. Any offer for sale or distribution of unregistered medications in Brazil constitutes a violation of sanitary surveillance regulations, with potential regulatory and criminal consequences.
What to do next
- Apreender o medicamento Lipoland (Tizerpartida)
- Proibir a importação, a comercialização, a distribuição, a propaganda e o uso do medicamento
Archived snapshot
Apr 25, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Notícias
Sem registro
Anvisa determina apreensão de medicamento Lipoland
Produto não possui registro e teve importação e uso proibidos Compartilhe: Publicado em 24/04/2026 18h05 Atualizado em 24/04/2026 19h06 A Anvisa determinou, n a quarta-feira (22/04), a apreensão do medicamento Lipoland (Tizerpartida), em todas as apresentações e dosagens. O produto é produzido por empresa desconhecida e não tem registro no Brasil.
A medida também proíbe a importação, a comercialização, a distribuição, a propaganda e o uso do medicamento.
Como se trata de medicamento sem registro no Brasil, não há informações que garantam os padrões de segurança e eficácia. Assim, não pode ser ofertado no páis.
Confira a Resolução no Diário Oficial da União
Frasco de produto sem registro no Brasil
Categoria Saúde e Vigilância Sanitária
Tags: Lipoland Irregular Compartilhe:
Related changes
Get daily alerts for Brazil ANVISA
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from ANVISA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Brazil ANVISA publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.